MXPA02012817A - Drogas antineoplasicas liposomales y uso de las mismas. - Google Patents

Drogas antineoplasicas liposomales y uso de las mismas.

Info

Publication number
MXPA02012817A
MXPA02012817A MXPA02012817A MXPA02012817A MXPA02012817A MX PA02012817 A MXPA02012817 A MX PA02012817A MX PA02012817 A MXPA02012817 A MX PA02012817A MX PA02012817 A MXPA02012817 A MX PA02012817A MX PA02012817 A MXPA02012817 A MX PA02012817A
Authority
MX
Mexico
Prior art keywords
compositions
antineoplastic drugs
liposomal
liposomal antineoplastic
methods
Prior art date
Application number
MXPA02012817A
Other languages
English (en)
Inventor
Quet F Ahkong
Original Assignee
Inex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Inc filed Critical Inex Pharmaceuticals Inc
Publication of MXPA02012817A publication Critical patent/MXPA02012817A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Esta invencion se refiere a agentes antineoplasicos liposomales (e.g. camptotecina) composiciones y metodos para utilizar tales composiciones para tratar neoplasia y para inhibir la angiogenesis. Las composiciones y metodos son utiles para modular la vida media en circulacion en plasma de un agente activo.
MXPA02012817A 2000-06-30 2001-06-29 Drogas antineoplasicas liposomales y uso de las mismas. MXPA02012817A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21555600P 2000-06-30 2000-06-30
US26461601P 2001-01-26 2001-01-26
PCT/CA2001/000925 WO2002002077A2 (en) 2000-06-30 2001-06-29 Liposomal antineoplastic drugs and uses thereof

Publications (1)

Publication Number Publication Date
MXPA02012817A true MXPA02012817A (es) 2004-07-30

Family

ID=26910152

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012817A MXPA02012817A (es) 2000-06-30 2001-06-29 Drogas antineoplasicas liposomales y uso de las mismas.

Country Status (12)

Country Link
US (7) US7060828B2 (es)
EP (2) EP1299085B1 (es)
JP (3) JP2004501955A (es)
CN (1) CN1245977C (es)
AT (2) ATE309786T1 (es)
AU (3) AU2001270385B2 (es)
CA (2) CA2412790C (es)
DE (2) DE60115045T2 (es)
ES (1) ES2253398T3 (es)
IL (2) IL153676A0 (es)
MX (1) MXPA02012817A (es)
WO (2) WO2002002078A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
CA2412790C (en) * 2000-06-30 2012-11-06 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US7452550B2 (en) * 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
CA2505520C (en) * 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
EP1686959B1 (en) * 2003-11-14 2009-06-24 HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute) Pharmaceutical formulations employing short-chain sphingolipids and their use
WO2005072776A2 (en) * 2004-01-30 2005-08-11 Instytut Farmaceutyczny Liposomal formulations of the antineoplastic agents
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
EP3173073A1 (en) 2004-05-03 2017-05-31 Merrimack Pharmaceuticals, Inc. Liposomes for drug delivery
ATE450251T1 (de) * 2004-05-17 2009-12-15 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CN101001633A (zh) * 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
KR100889139B1 (ko) * 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
WO2006014035A1 (en) * 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
AU2005291807B2 (en) * 2004-10-06 2012-04-19 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
CN100348194C (zh) * 2005-07-26 2007-11-14 康辰医药发展有限公司 盐酸洛拉曲克的脂质体制剂及其制备方法
CN100375621C (zh) * 2005-11-04 2008-03-19 唐星 长春瑞滨脂质微球注射液及其制备方法
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEUROTHERAPY OF HIGH MOLECULAR WEIGHT ENHANCED BY CONVECTION
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
US20100093873A1 (en) * 2008-10-02 2010-04-15 Goldfischer Sidney L Methods of improving therapy of perfluorocarbons (PFC)
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
WO2011085815A1 (en) 2010-01-14 2011-07-21 Brainlab Ag Controlling a surgical navigation system
WO2012058666A2 (en) * 2010-10-29 2012-05-03 Health Research, Inc. Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10349884B2 (en) * 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US8753674B2 (en) * 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10449193B2 (en) * 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US20190320975A1 (en) * 2011-06-03 2019-10-24 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN105025904A (zh) 2012-09-04 2015-11-04 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
KR102186116B1 (ko) 2012-11-20 2020-12-03 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
CA2913023C (en) * 2013-05-30 2021-06-08 Nanobiotix Pharmaceutical composition, preparation and uses thereof
ES2940564T3 (es) 2013-12-18 2023-05-09 Signpath Pharma Inc Mitigación liposómica de la inhibición inducida por fármaco del canal IKr cardíaco
EP3151837B1 (en) 2014-06-03 2023-03-15 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
FI3229776T3 (fi) * 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
CN108366965B (zh) 2015-10-16 2021-10-01 易普森生物制药有限公司 稳定喜树碱药物组合物
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
KR102181659B1 (ko) 2016-04-27 2020-11-24 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
KR102493872B1 (ko) 2016-09-02 2023-01-30 다이서나 파마수이티컬, 인크. 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
MX2019004783A (es) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina).
AU2018246024B2 (en) 2017-03-31 2020-08-06 Fujifilm Corporation Liposome composition and pharmaceutical composition
CA3090943A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
TWI737974B (zh) * 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
JP2021521279A (ja) * 2018-04-11 2021-08-26 ニュー メキシコ テック ユニバーシティ リサーチ パーク コーポレーション 薬物送達における使用のための脂質プロドラッグ
EP3811931A4 (en) 2018-06-20 2021-08-04 FUJIFILM Corporation COMBINATION MEDICINE WITH LIPOSOME COMPOSITION FOR ENCAPSULATING A ACTIVE SUBSTANCE AND IMMUNCHECKPOINT INHIBITOR
WO2020071349A1 (ja) 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
KR20210145213A (ko) 2019-03-29 2021-12-01 다이서나 파마수이티컬, 인크. Kras 관련 질환 또는 장애를 치료하기 위한 조성물 및 방법
AU2020268798A1 (en) 2019-05-03 2021-11-04 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
EP4076400A1 (en) * 2019-12-20 2022-10-26 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
IL294599A (en) 2020-01-15 2022-09-01 Dicerna Pharmaceuticals Inc Methylene phosphonate nucleic acids and their analogs
WO2022031433A1 (en) 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
WO2022250015A1 (ja) 2021-05-24 2022-12-01 富士フイルム株式会社 処置剤
CN117440810A (zh) 2021-05-24 2024-01-23 富士胶片株式会社 抗肿瘤剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
JPS63502117A (ja) * 1986-02-10 1988-08-18 リポソ−ム　テクノロジ−，インコ−ポレイテッド 放出を制御されたリポソ−ム供給系
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US6855331B2 (en) * 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
KR970705997A (ko) * 1994-10-05 1997-11-03 그래함 브레레톤 N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a)
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
WO1996040964A2 (en) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4990397A (en) * 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
DE69907243T2 (de) 1998-09-16 2004-02-19 Alza Corp., Mountain View In liposomen eingeschlossene topoisomerase inhibitoren
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
CA2412790C (en) * 2000-06-30 2012-11-06 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
CN1469735A (zh) * 2000-10-16 2004-01-21 ����˹��ҩ�﹫˾ 米托蒽醌的脂质体制剂
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline

Also Published As

Publication number Publication date
US20060093662A1 (en) 2006-05-04
IL153676A (en) 2007-06-17
US20110086826A1 (en) 2011-04-14
US20060269594A1 (en) 2006-11-30
WO2002002078A2 (en) 2002-01-10
CN1446079A (zh) 2003-10-01
CA2412790C (en) 2012-11-06
CA2412795C (en) 2012-10-02
JP2014088444A (ja) 2014-05-15
AU7038501A (en) 2002-01-14
CA2412790A1 (en) 2002-01-10
US7244448B2 (en) 2007-07-17
EP1299085A2 (en) 2003-04-09
EP1299085B1 (en) 2005-11-16
AU2001270385B2 (en) 2006-05-25
US20020110586A1 (en) 2002-08-15
DE60115044T2 (de) 2006-08-03
EP1299084B1 (en) 2005-11-16
US20020119990A1 (en) 2002-08-29
EP1299084A2 (en) 2003-04-09
WO2002002077A2 (en) 2002-01-10
JP2012092148A (ja) 2012-05-17
WO2002002078A3 (en) 2002-12-27
ES2253398T3 (es) 2006-06-01
CN1245977C (zh) 2006-03-22
DE60115044D1 (de) 2005-12-22
US20130136787A1 (en) 2013-05-30
ATE309787T1 (de) 2005-12-15
DE60115045T2 (de) 2006-08-03
AU2001270413A1 (en) 2002-01-14
ATE309786T1 (de) 2005-12-15
WO2002002077A3 (en) 2002-12-12
US7060828B2 (en) 2006-06-13
IL153676A0 (en) 2003-07-06
CA2412795A1 (en) 2002-01-10
JP2004501955A (ja) 2004-01-22
US20040170678A1 (en) 2004-09-02
DE60115045D1 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
MXPA02012817A (es) Drogas antineoplasicas liposomales y uso de las mismas.
DE60112609D1 (en) Pyrazolopyridine
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
AU7315301A (en) Compounds and compositions for delivering active agents
PL347671A1 (en) Compounds and compositions for delivering active agents
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
HK1036970A1 (en) Compounds and compositions for delivering active agents.
AP9901478A0 (en) Compounds for the treatment of ischemia.
HK1048990A1 (en) Novel compounds.
PL366198A1 (en) Novel compounds
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
AU2002239348A1 (en) Pyrazolopyridine derivatives
DK1226148T3 (da) Hidtil ukendte oligosaccharider, fremstilling heraf og farmaceutiske præparater, der indeholder dem
MXPA03002911A (es) Compuestos quimicos.
TNSN03060A1 (en) A combination comprising combretastatin and anticancer agents
AU6469401A (en) Pharmaceutically active compounds and methods of use
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
DE60201074D1 (en) Pyrazolopyridinderivate
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
SE9904128D0 (sv) Novel compounds
AP2001002369A0 (en) Pharmaceutical complex.
WO2003053365A3 (en) Syn3 compositions and methods
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
GB Transfer or rights